Published in Pharmaceuticals (Basel) on June 04, 2012
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease | NCT00985517
Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease | NCT00252850
Personalizing health care: feasibility and future implications. BMC Med (2013) 1.07
CRF-amplified neuronal TLR4/MCP-1 signaling regulates alcohol self-administration. Neuropsychopharmacology (2015) 0.93
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A (1992) 35.45
In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (1996) 28.95
Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A (1996) 9.15
Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol (1998) 8.45
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci (1973) 7.85
Primate models of movement disorders of basal ganglia origin. Trends Neurosci (1990) 7.63
Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A (1990) 7.06
Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet (2007) 7.01
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology (2006) 6.86
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol (2008) 6.82
GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science (1993) 6.73
Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A (1994) 6.61
Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol (1996) 6.22
Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med (2001) 6.07
The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci (2002) 5.93
Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci U S A (1982) 5.73
Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med (1999) 5.50
Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet (1994) 5.49
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol (2006) 5.49
Aromatic amino acids and modification of parkinsonism. N Engl J Med (1967) 5.46
Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med (2003) 4.51
Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A (2000) 4.39
Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther (2006) 4.36
AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol (2011) 4.23
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol (2008) 4.16
Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science (2000) 3.89
Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell (1985) 3.86
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science (1990) 3.74
A humanized system for pharmacologic control of gene expression. Nat Med (1996) 3.69
Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol (2011) 3.45
Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev (2008) 3.30
Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem (2001) 3.15
Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet (1995) 3.06
The Trk family of neurotrophin receptors. J Neurobiol (1994) 3.06
Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol (2000) 2.98
Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat Neurosci (2008) 2.93
Characterization of a multicomponent receptor for GDNF. Nature (1996) 2.92
GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell (1996) 2.86
Virus isolation from and identification of HTLV-III/LAV-producing cells in brain tissue from a patient with AIDS. JAMA (1986) 2.86
Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology (2008) 2.80
Specific tropism of HIV-1 for microglial cells in primary human brain cultures. Science (1990) 2.74
Two forms of the gamma-aminobutyric acid synthetic enzyme glutamate decarboxylase have distinct intraneuronal distributions and cofactor interactions. J Neurochem (1991) 2.66
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology (2003) 2.65
The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology (2009) 2.62
Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med (1998) 2.58
Reducing hemorrhagic complications in functional neurosurgery: a large case series and systematic literature review. J Neurosurg (2011) 2.53
Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg (2005) 2.53
Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol (1997) 2.52
Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther (2006) 2.41
Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N Engl J Med (1992) 2.39
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology (2009) 2.37
Deep brain stimulation for Parkinson's disease. Curr Opin Neurobiol (2003) 2.36
Functional recovery in parkinsonian monkeys treated with GDNF. Nature (1996) 2.35
GDNF signalling through the Ret receptor tyrosine kinase. Nature (1996) 2.21
Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease. Ann Neurol (1998) 2.21
Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J Neurosci (2010) 2.15
Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature (1996) 2.09
Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg (2005) 2.07
Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome. J Virol (1997) 2.06
Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) N Engl J Med (1992) 2.01
Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science (1994) 1.98
Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg (1999) 1.97
Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet (1977) 1.96
Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology (2005) 1.95
Two human glutamate decarboxylases, 65-kDa GAD and 67-kDa GAD, are each encoded by a single gene. Proc Natl Acad Sci U S A (1992) 1.93
The structural and functional heterogeneity of glutamic acid decarboxylase: a review. Neurochem Res (1991) 1.93
Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production. Gene Ther (2005) 1.93
Systematic determination of the packaging limit of lentiviral vectors. Hum Gene Ther (2001) 1.88
Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol (2005) 1.86
Regulation of gamma-aminobutyric acid synthesis in the brain. J Neurochem (1993) 1.86
GABA and GABA receptors in the central nervous system and other organs. Int Rev Cytol (2002) 1.84
Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature (1996) 1.83
Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg (2002) 1.79
Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics (2008) 1.79
Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp Neurol (2005) 1.78
Focal delivery during direct infusion to brain: role of flow rate, catheter diameter, and tissue mechanics. Am J Physiol (1999) 1.77
A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys. Mol Ther (2006) 1.77
Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol (1999) 1.75
A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis. Mol Ther (2007) 1.75
Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain Res Brain Res Protoc (2005) 1.74
Neurotrophic factors and their receptors. Curr Opin Cell Biol (1995) 1.74
Gene transfer vectors derived from equine infectious anemia virus. Gene Ther (1998) 1.74
Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Exp Neurol (2003) 1.72
Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum Gene Ther (2006) 1.72
Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc Natl Acad Sci U S A (2009) 1.70
Real-time imaging of convection-enhanced delivery of viruses and virus-sized particles. J Neurosurg (2007) 1.68
A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther (2010) 1.68
Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector. Curr Opin Drug Discov Devel (2003) 1.65
Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson's disease. N Engl J Med (1987) 1.62
Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. J Neurosci (1998) 1.59
Adeno-associated virus type 2-mediated gene transfer: role of cellular FKBP52 protein in transgene expression. J Virol (2001) 1.58
Glial cell line-derived neurotrophic factor activates the receptor tyrosine kinase RET and promotes kidney morphogenesis. Proc Natl Acad Sci U S A (1996) 1.58
Image-guided, direct convective delivery of glucocerebrosidase for neuronopathic Gaucher disease. Neurology (2006) 1.57
Real-time MR imaging of adeno-associated viral vector delivery to the primate brain. Neuroimage (2008) 1.53
Direct convective delivery of macromolecules to the spinal cord. J Neurosurg (1998) 1.53
Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity. Mol Ther (2009) 1.52
Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in rhesus monkeys. Toxicol Pathol (2007) 1.52
Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note. J Neurosurg (2007) 1.51
Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science (2002) 8.41
Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med (2010) 4.45
PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med (2010) 3.48
Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther (2012) 2.42
Dysregulation of gene expression in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse substantia nigra. J Neurosci (2004) 2.24
Apoptosis-inducing factor substitutes for caspase executioners in NMDA-triggered excitotoxic neuronal death. J Neurosci (2004) 2.17
Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics (2008) 1.79
Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp Neurol (2005) 1.78
A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys. Mol Ther (2006) 1.77
Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain Res Brain Res Protoc (2005) 1.74
Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum Gene Ther (2012) 1.70
Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc Natl Acad Sci U S A (2009) 1.70
Neuronal precursor-restricted transduction via in utero CNS gene delivery of a novel bipartite HSV amplicon/transposase hybrid vector. Mol Ther (2006) 1.69
Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J Neuroinflammation (2005) 1.64
Synuclein activates microglia in a model of Parkinson's disease. Neurobiol Aging (2007) 1.63
Combined delivery of Nogo-A antibody, neurotrophin-3 and the NMDA-NR2d subunit establishes a functional 'detour' in the hemisected spinal cord. Eur J Neurosci (2011) 1.62
An engineered zinc finger protein activator of the endogenous glial cell line-derived neurotrophic factor gene provides functional neuroprotection in a rat model of Parkinson's disease. J Neurosci (2010) 1.59
Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am J Pathol (2008) 1.55
Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. Hum Gene Ther (2009) 1.55
Viral delivery of NR2D subunits reduces Mg2+ block of NMDA receptor and restores NT-3-induced potentiation of AMPA-kainate responses in maturing rat motoneurons. J Neurophysiol (2004) 1.55
Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. Mol Ther (2012) 1.55
Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol (2012) 1.54
Real-time MR imaging of adeno-associated viral vector delivery to the primate brain. Neuroimage (2008) 1.53
The evolution of gene transfer, gene therapy, and the RAC: IOM recommendations to the NIH director. Mol Ther (2014) 1.53
Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Hum Gene Ther (2013) 1.52
Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp Neurol (2002) 1.51
Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Mol Ther (2011) 1.50
Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther (2009) 1.46
Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain. Mol Ther (2008) 1.40
Brn3b/Brn3c double knockout mice reveal an unsuspected role for Brn3c in retinal ganglion cell axon outgrowth. Development (2002) 1.37
Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res (2006) 1.36
Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. Hum Gene Ther (2009) 1.36
Blockade of gap junctions in vivo provides neuroprotection after perinatal global ischemia. Stroke (2005) 1.36
Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc Natl Acad Sci U S A (2002) 1.33
Exome sequencing in an SCA14 family demonstrates its utility in diagnosing heterogeneous diseases. Neurology (2012) 1.33
Striatal volume differences between non-human and human primates. J Neurosci Methods (2008) 1.33
Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Mol Ther (2010) 1.32
Effects of the perivascular space on convection-enhanced delivery of liposomes in primate putamen. Exp Neurol (2005) 1.32
Endothelin-1 regulates cardiac sympathetic innervation in the rodent heart by controlling nerve growth factor expression. J Clin Invest (2004) 1.31
Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther (2010) 1.31
Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain. Stereotact Funct Neurosurg (2011) 1.30
Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro Oncol (2006) 1.29
The good, the bad, and the cell type-specific roles of hypoxia inducible factor-1 alpha in neurons and astrocytes. J Neurosci (2008) 1.27
Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro Oncol (2006) 1.26
Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res (2004) 1.26
Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation. J Neurosurg (2008) 1.25
Optimized cannula design and placement for convection-enhanced delivery in rat striatum. J Neurosci Methods (2009) 1.25
Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates. Neuroimage (2009) 1.24
Real-time imaging and quantification of brain delivery of liposomes. Pharm Res (2006) 1.22
Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Hum Gene Ther (2009) 1.21
Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro Oncol (2007) 1.21
The endoplasmic reticulum stress response factor CHOP-10 protects against hypoxia-induced neuronal death. J Biol Chem (2010) 1.19
Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease? Brain Res Mol Brain Res (2005) 1.19
Measuring the frequency of mouse and human cytotoxic T cells by the Lysispot assay: independent regulation of cytokine secretion and short-term killing. Nat Med (2003) 1.17
Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: implications for local drug delivery. J Neurosci Methods (2006) 1.17
Safety of real-time convection-enhanced delivery of liposomes to primate brain: a long-term retrospective. Exp Neurol (2007) 1.14
Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. J Neurosci (2010) 1.14
HSV ICP0 recruits USP7 to modulate TLR-mediated innate response. Blood (2008) 1.14
Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson's disease. Neurobiol Dis (2005) 1.12
Reporter gene transfer induces apoptosis in primary cortical neurons. Mol Ther (2002) 1.11
Microglial activation and antioxidant responses induced by the Parkinson's disease protein α-synuclein. J Neuroimmune Pharmacol (2012) 1.09
Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors. Mol Ther (2010) 1.09
Visual deficits in a mouse model of Batten disease are the result of optic nerve degeneration and loss of dorsal lateral geniculate thalamic neurons. Neurobiol Dis (2006) 1.08
Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy. Hum Gene Ther (2014) 1.08
Mutant alpha-synuclein overexpression mediates early proinflammatory activity. Neurotox Res (2009) 1.08
Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. Neurosurg Focus (2006) 1.06
Abeta-directed single-chain antibody delivery via a serotype-1 AAV vector improves learning behavior and pathology in Alzheimer's disease mice. Mol Ther (2010) 1.06
An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons. Brain Res (2011) 1.05
Qualitative imaging of adeno-associated virus serotype 2-human aromatic L-amino acid decarboxylase gene therapy in a phase I study for the treatment of Parkinson disease. Neurosurgery (2010) 1.05
The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. Cancer Res (2006) 1.04
AAV9: over the fence and into the woods . . . Mol Ther (2011) 1.04
Helper-free HSV-1 amplicons elicit a markedly less robust innate immune response in the CNS. Mol Ther (2003) 1.03
Reduced pathology and improved behavioral performance in Alzheimer's disease mice vaccinated with HSV amplicons expressing amyloid-beta and interleukin-4. Mol Ther (2008) 1.02
Image-guided convection-enhanced delivery of GDNF protein into monkey putamen. Neuroimage (2010) 1.02
Neurotrophin-3 transduction attenuates cisplatin spiral ganglion neuron ototoxicity in the cochlea. Mol Ther (2002) 1.02
Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum. Hum Gene Ther (2012) 1.02
Alpha-synuclein mediates alterations in membrane conductance: a potential role for alpha-synuclein oligomers in cell vulnerability. Eur J Neurosci (2010) 1.01
Trk retrograde signaling requires persistent, Pincher-directed endosomes. Proc Natl Acad Sci U S A (2010) 1.00
HUMMR, a hypoxia- and HIF-1alpha-inducible protein, alters mitochondrial distribution and transport. J Cell Biol (2009) 0.99
Cannula placement for effective convection-enhanced delivery in the nonhuman primate thalamus and brainstem: implications for clinical delivery of therapeutics. J Neurosurg (2010) 0.99
Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease. Mol Ther (2008) 0.98
Canine spontaneous glioma: a translational model system for convection-enhanced delivery. Neuro Oncol (2010) 0.97
Convection-enhanced delivery of liposomes to primate brain. Methods Enzymol (2009) 0.96
p75 neurotrophin receptor protects primary cultures of human neurons against extracellular amyloid beta peptide cytotoxicity. J Neurosci (2003) 0.96
Current treatment for Alzheimer disease and future prospects. Alzheimer Dis Assoc Disord (2003) 0.96
Loss of c/EBP-beta activity promotes the adaptive to apoptotic switch in hypoxic cortical neurons. Mol Cell Neurosci (2008) 0.96
Microarrays in Parkinson's disease: a systematic approach. NeuroRx (2006) 0.96
An improved method for generating consistent soluble amyloid-beta oligomer preparations for in vitro neurotoxicity studies. J Neurosci Methods (2010) 0.95
CNS delivery of vectored prion-specific single-chain antibodies delays disease onset. Mol Ther (2008) 0.94
Altered gene expression profiles reveal similarities and differences between Parkinson disease and model systems. Neuroscientist (2005) 0.93
Design of an in-dwelling cannula for convection-enhanced delivery. J Neurosci Methods (2010) 0.93
T2 imaging in monitoring of intraparenchymal real-time convection-enhanced delivery. Neurosurgery (2011) 0.93
Temporal and spatial localization of nectin-1 and l-afadin during synaptogenesis in hippocampal neurons. J Comp Neurol (2008) 0.93
Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain. Neurobiol Dis (2011) 0.93